ARCUTIS BIOTHERAPEUTICS INC's ticker is ARQT and the CUSIP is 03969K108. A total of 64 filers reported holding ARCUTIS BIOTHERAPEUTICS INC in Q3 2020. The put-call ratio across all filers is - and the average weighting 0.8%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $136,255 | -42.2% | 25,660 | +3.7% | 0.00% | 0.0% |
| Q2 2023 | $235,848 | +7.0% | 24,748 | +23.5% | 0.00% | 0.0% |
| Q1 2023 | $220,352 | -24.2% | 20,032 | +2.0% | 0.00% | -50.0% |
| Q4 2022 | $290,568 | -21.7% | 19,633 | +1.2% | 0.00% | -33.3% |
| Q3 2022 | $371,000 | +6.3% | 19,400 | +18.3% | 0.00% | +50.0% |
| Q2 2022 | $349,000 | +32.2% | 16,394 | +19.4% | 0.00% | +100.0% |
| Q1 2022 | $264,000 | -13.4% | 13,733 | -6.6% | 0.00% | -50.0% |
| Q4 2021 | $305,000 | -15.7% | 14,700 | -2.9% | 0.00% | 0.0% |
| Q3 2021 | $362,000 | -14.4% | 15,139 | -2.3% | 0.00% | +100.0% |
| Q2 2021 | $423,000 | +8.5% | 15,499 | +15.1% | 0.00% | 0.0% |
| Q1 2021 | $390,000 | +15.0% | 13,471 | +11.9% | 0.00% | 0.0% |
| Q4 2020 | $339,000 | +6.9% | 12,038 | +11.4% | 0.00% | -50.0% |
| Q3 2020 | $317,000 | +81.1% | 10,810 | +86.5% | 0.00% | +100.0% |
| Q2 2020 | $175,000 | -4.9% | 5,797 | -5.9% | 0.00% | 0.0% |
| Q1 2020 | $184,000 | – | 6,159 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Frazier Life Sciences Management, L.P. | 8,684,232 | $46,113,272 | 3.06% |
| Pivotal bioVenture Partners Investment Advisor LLC | 1,105,309 | $5,869,191 | 2.34% |
| Bain Capital Life Sciences Investors, LLC | 3,000,000 | $15,930,000 | 1.78% |
| Sio Capital Management, LLC | 635,969 | $3,376,995 | 1.04% |
| Rubric Capital Management LP | 5,034,530 | $26,733,354 | 1.00% |
| Tejara Capital Ltd | 309,179 | $1,641,740 | 0.93% |
| AlphaCentric Advisors LLC | 165,000 | $876,150 | 0.50% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 1,135,227 | $6,028,055 | 0.33% |
| Orbimed Advisors | 1,914,479 | $10,165,883 | 0.22% |
| Two Seas Capital LP | 164,807 | $875,125 | 0.18% |